Department of Biochemistry, All India Institute of Medical Sciences, Room no. 3002, Ansari Nagar, New Delhi, India.
Arch Virol. 2010 Apr;155(4):563-9. doi: 10.1007/s00705-010-0605-4. Epub 2010 Feb 24.
The viral reverse transcriptase gene was amplified from the plasma of 27 drug-naïve and five drug-experienced HIV patients in Northern India. Follow-up samples of naïve patients after antiretroviral therapy initiation were collected in six patients at 3 months and three patients at 6 months. Phylogenetic analysis revealed two new recombinant forms, CRF_CH and CRF_CK, and an accessory non-nucleoside reverse transcriptase inhibitor mutation E138A, not previously reported from India. The major DRMs found in two 6-month follow-up samples were absent in their baseline blood samples. This is the first follow-up study to determine anti-retroviral drug resistance mutations in Indian HIV patients.
从印度北部的 27 名未经治疗的患者和 5 名有治疗史的患者的血浆中扩增出了病毒逆转录酶基因。在开始抗逆转录病毒治疗后，对 6 名患者的 3 个月和 3 名患者的 6 个月时的未经治疗患者的随访样本进行了采集。系统进化分析显示了两种新的重组形式 CRF_CH 和 CRF_CK，以及此前在印度未报告过的一种辅助非核苷类逆转录酶抑制剂突变 E138A。在两个 6 个月随访样本中发现的主要耐药突变在其基线血液样本中不存在。这是首次对印度 HIV 患者的抗逆转录病毒药物耐药性突变进行的随访研究。
